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DOI 10.1186/s12879-015-1158-7RESEARCH ARTICLE Open AccessReduced uptake of mass treatment for
schistosomiasis control in absence of food:
beyond a randomized trial
Simon Muhumuza1*, Annette Olsen2, Anne Katahoire1 and Fred Nuwaha3Abstract
Background: Sustaining high uptake of praziquantel is key for long-term control of schistosomiasis. During mass
treatment in 2013, we randomized 12 primary schools into two groups; one group received education messages
for schistosomiasis prevention for two months prior to mass treatment, while the other, in addition to the
education messages, received a pre-treatment snack shortly before mass treatment. The uptake of praziquantel in
the snack schools was 94 % compared to 79 % in the non-snack schools. During mass treatment in 2014, no snack
was provided. We compared the uptake of praziquantel in 2014 to that in 2013 and attempt to explain the reasons
for the observed differences.
Methods: Serial cross sectional surveys were conducted among a random sample of children from the 12 primary
schools, 1 month after mass treatment in 2013 and 2014 to measure uptake of praziquantel, reported side effects
attributable to praziquantel and prevalence and intensity of schistosomiasis infection. Differences in the
demographic and descriptive variables between the 2013 and 2014 samples were compared using chi squared
tests for categorical variables and student’s t-test for geometric mean intensity of S. mansoni infection.
Results: Uptake of praziquantel reduced from 93.9 to 78.0 % (p = 0.002) in the snack schools but was unchanged in
the non-schools 78.7 and 70.4 % (p = 0.176). The occurence of side-effects attributable to praziquantel increased
from 34.4 to 61.2 % (p = 0.001) in the snack schools but was unchanged in the non-snack schools; 46.9 and 53.2 %
(p = 0.443). Although the prevalence of S. mansoni infection increased in both the snack and non-snack schools, the
differences did not reach statistical significance;1.3 and 7.5 % (p = 0.051) and 14.1 and 22.0 % (p = 0.141), respectively.
Similarly, the difference in the geometric mean intensity of S. mansoni infection in both the snack and non-snack
schools was not statistically significant; 38.3 eggs per gram of stool (epg) and 145.7 epg (p = 0.197) and 78.4 epg and
322.5 epg (p = 0.120), respectively.
Conclusion: Our results show that in absence of food, uptake of praziquantel reduced and the side-effects of the drug
increased. However, the reduced uptake did not affect the prevalence and intensity of schistosomiasis among school
children. Rescinding of the provision of the snack is what probably caused the reduction in uptake of treatment in the
subsequent mass treatment cycle.
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The goal of the Ugandan national schistosomiasis con-
trol program is morbidity control through regular mass
treatment in endemic areas [1]. Annual school-based
mass treatment with praziquantel is the cornerstone for
schistosomiasis control among school-aged children.
The school approach is based on the premises that it is
cost-effective to deliver interventions through the school
system because schools are widely distributed and that
school teachers can assist to administer the drugs to the
children [2–5]. The drawbacks of this strategy have been
documented in many parts of the country. The reliance
on volunteer teachers to distribute treatment, the fear of
side-effects of praziquantel, low school attendance rates
and the social, economic and political context in which
mass treatment is rolled out profoundly affect the uptake
of drugs among the targeted population [6–9]. In some
locations, uptake of treatment has been found to be low
[8–11]. The target is to treat at least 75 % of school-age
children at risk of morbidity [12]. In a particular study
conducted in Jinja district, less than 30 % of the school
children took praziquantel during mass treatment in
2011. The fear of treatment, inadequate health educa-
tion and lack of teacher support were some of the fac-
tors thought to influence the uptake [11]. In an effort to
increase the uptake of treatment in 2012, the national
control program motivated the teachers to distribute
treatment through provision of incentives and intensi-
fied supervision with little success [13].
Praziquantel should be concurrently administered with
food to mitigate the side effects of the drug and increase
its uptake [14–16]. Studies assessing the use of food in-
centives have shown improved participation of children
in health programs for treatment of schistosomiasis,
HIV/AIDS and other diseases [16–19]. Furthermore, the
use of food is associated with improved treatment out-
comes and education benefits among school children
[17, 20, 21]. In Uganda, the school feeding policy re-
quires that parents take responsibility for feeding their
children while at school [22]. However, due to the pre-
vailing poverty in many parts of the country, most par-
ents cannot afford to meet the cost of a daily meal for
their children while at school [23]. In areas where annual
treatment with praziquantel for schistosomiasis control
is provided, most children take the treatment on an
empty stomach and experience side effects [24, 25] and
as such, reject the drug during the subsequent mass
treatment programs [9, 26].
Strategies for improving uptake, such as provision of
food to mitigate the side effects of praziquantel and mo-
tivate children to take treatment are required. Our study
conducted in 2013 demonstrated the effectiveness of a
pre-treatment snack on the uptake of praziquantel
among school children [27]. This study compares the2013 uptake with the 2014 uptake when no snack was
provided. In addition, the reported side effects attribut-
able to praziquantel and prevalence and intensity of
schistosomiasis infection are compared.
Methods
Ethical considerations
Ethical permit to conduct the study was obtained from
the School of Medicine Research and Ethics Committee,
Makerere University and the Uganda National Council
for Science and Technology. Clearance to conduct the
study in the schools was obtained from the school man-
agement. Written informed consent from the parents
and guardians of the children was obtained through
half-day meetings held at the respective schools. Assent
to participate in the study was obtained from all the
children. Children identified with schistosomiasis and/or
STH were treated with praziquantel and/or albendazole.
Study design
Serial cross sectional surveys were carried out 1 month
after mass treatment in 2013 and 2014. Both surveys
employed similar quantitative methods of data
collection.
Study setting
The surveys were carried out in 12 primary schools of
Walukuba division, Jinja district of south eastern
Uganda, where intestinal schistosomiasis is highly en-
demic. This setting has been described in our earlier
studies [11, 26, 27]. Briefly, annual school-based mass
treatment is implemented as the main strategy for schis-
tosomiasis control in the division. Treatment to the
school children is distributed and registered by trained
teachers who are supervised by sub-county health assis-
tants and inspector of schools. However, uptake of prazi-
quantel among school children in the area was low. Prior
to the 2013 mass treatment, the 12 primary schools in the
division were randomized into two groups; one received
education messages for schistosomiasis prevention for two
months prior to mass treatment, while the other, in
addition to the education messages, received a snack be-
fore mass treatment. Each child in the snack schools re-
ceived 500 ml of mango juice and a doughnut shortly
before swallowing praziquantel during mass treatment.
The education messages focused on the prevention as-
pects of schistosomiasis infection including taking pre-
ventive treatment (praziquantel) with food in order to
avoid the side-effects of the drugs. Both the snack and the
education messages were delivered by the teachers. These
interventions were supported by the Danish Ministry of
Foreign Affairs. The uptake of praziquantel in the snack
schools (93.9 %) was considerably higher than in the non-
snack schools (78.7 %). The occurrence of the side effects
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S. mansoni infection were considerably lower in the snack
schools than in the non-snack schools [27]. Prior to the
2014 mass treatment, information about mass drug distri-
bution was communicated through radio talk shows and
spot messages. However, there was no snack provided to
the children prior to treatment.
Sample size
The uptake of praziquantel used to estimate the sample
size for this study was derived from our previous study.
It was assumed that uptake of treatment would decrease
from 94 % in 2013 [27] to 75 % in 2014. At a 90 %
power and a 95 % CI, the sample size required to test
this difference was 85 in the snack schools and 85 in the
non-snack schools according to STATA 12.0 (TX, USA).
Because of the cluster design, a design effect of 6.3 from
the previous study was applied to obtain a minimum
sample size of 536 in the snack schools and 536 in the
non-snack schools. In this study, 1,142 children were
randomly selected from the 12 primary schools to par-
ticipate in the 2014 study.
Sampling and data collection
Similar sampling and data collection methods as those
used in the previous study were employed [27]. Children
in the two groups were randomly selected from grade
(year) 4–6. A proportionate number of children selected
from each school and grade was determined by prob-
ability proportional to size of the school and grade
population. Systematic sampling was used to select the
children from each grade to participate in the face to
face interviews using a structured questionnaire and
undergo a stool examination for S. mansoni infection
using the modified Kato-Katz thick smear technique
with a 41.7 mg template [28].
Measures
Measures included self-reported uptake of praziquantel,
occurrence of side-effects and prevalence and intensity
of S. mansoni infection in the two groups. In addition,
the socio-demographic characteristics of the children
and their knowledge of schistosomiasis prevention were
assessed. Uptake of praziquantel was measured on a
score scale of 1–4. Children were asked whether they re-
ceived treatment, and if they did, they were further
asked the colour and the taste of the tablets, and
whether they swallowed the drugs. For each positive re-
sponse, a score of one was awarded. Children who re-
ported to have received the drug, mentioned the true
colour and taste of praziquantel and reported to have
swallowed the tablets scored an aggregate of four and
this was considered as true uptake of praziquantel. In
addition, children who reported to have swallowedtreatment were asked if they developed any side effects
after swallowing the drug. Knowledge of schistosomiasis
prevention was measured on a score scale of 1–3. Chil-
dren were asked the different ways through which the
infection can be transmitted and prevented. For each of
the correct responses, a score of one was awarded. Chil-
dren who mentioned at least one correct method of
transmission and two correct methods of prevention
scored an aggregate of three and were regarded as hav-
ing correct knowledge of schistosomiasis prevention.
Laboratory diagnosis of S. mansoni infection
In order to determine the prevalence and intensity of S.
mansoni infection, we examined one early morning stool
specimen from each child on two consecutive days using
the modified Kato-Katz faecal thick smear technique
[28] with a 41.7 mg template. The Kato-Katz method was
adopted because it is simple, low cost and uses an already
established system to stratify infection intensities into dif-
ferent classes based on cut offs of egg-counts [29, 30].
Two slides per stool specimen were prepared and exam-
ined by two independent laboratory technicians. A dis-
crepancy of more than 5 % in egg counts was validated by
a third laboratory technician who read the results for con-
firmation and the counts harmonized. The egg counts
were found to be over dispersed and thus were logarith-
mically transformed and intensities reported as geometric
mean intensity (GMI) of eggs per gram of stool (epg)
among positive cases only.
Data management and statistical analysis
Data entry and validation was performed in Microsoft
Access 2007 and exported to STATA 12.0 (TX, USA) for
analysis. Analysis was done at both the cluster and indi-
vidual levels. Mean and standard deviation (S.D) were
used to describe continuous data. Differences in the
demographic and descriptive variables between the 2013
and 2014 children samples were compared using chi
squared tests for categorical variables. Student’s t-test
was used to compare mean intensity of S. mansoni infec-
tion. Multivariable regression was done to identify the
independent predictors of uptake of praziquantel. Clus-
tering was adjusted for by dividing test statistics based
on chi squared tests and the t- test with the design effect
and the square root of the design effect [31, 32], respect-
ively. The intracluster correlation coefficient (ICC) was
0.06 and the design effect was 6.3.
Quality control
Data were collected by experienced research assistants
who are fluent in the local language of Lusoga. Similar
data collection tools as those used in 2013 were
employed [27]. To ensure completeness and accuracy,
data were checked before leaving the field and as such,
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the research assistants during data collection.
Results
Demographic characteristics
Overall, a total of 2,426 children in 12 primary schools
were assessed one month after mass treatment in 2013
and 2014: 1,284 children in 2013 and another 1,142 in
2014. Of the 1,284 children assessed in 2013, 595
(46.3 %) were from the snack schools and 689 (53.7 %)
were from the non-snack schools. Of the 1,142 children
assessed in 2014, 496 (43.4 %) and 646 (56.6 %) were
from the snack and non-snack schools, respectively. The
mean age of children in the snack schools was
11.3 years (standard deviation [SD] 1.7) in 2013 and
11.6 years (SD 1.5) in 2014 while that in the non-snack
schools was 11.7 years (SD 1.6) in 2013 and 12.2 years
(SD 1.8) in 2014. Children in the snack and non-snack
schools in the 2013 and 2014 samples were comparable
in terms of age group, sex and distance from area of
residence to the lake (p > 0.05) (Table 1).
Self-reported uptake of praziquantel and occurrence of
side-effects
A significant decrease in uptake of praziquantel from
93.9 % (95 % CI 91.7–95.7 %) in 2013 to 78.0 % (95 % CI
74.1–81.6 %) (p = 0.002) in 2014 was observed in the
snack schools. However, uptake in the non-snack
schools was unchanged; 78.7 % (95 % CI 75.4–81.7 %) in
2013 and 70.4 % (95 % CI 66.7–73.9 %) (p = 0.176) in
2014 (Table 2). The 2014 uptake in the snack and non-
snack was comparable; 78.0 % (95 % CI 74.1–81.6 %) and
70.4 % (95 % CI 66.7–73.9 %) (p = 0.250), respectively.
A considerable increase in the occurrence of side-effects
attributable to praziquantel was observed in the snack
schools in 2013; from 34.4 % (95 % CI 31.5–39.8 %) in
2013 to 61.2 % (95 % CI 56.2–66.1 %) (p = 0.001) in 2014.Table 1 Comparison of the children in the two groups of schools a
Characteristic Non-snack schools
2013 2014 χ2a p-Va
n = (689) (%) n = (646) (%)
Age group
07–11 years 291 (42.2) 301 (46.6) 0.379 0.5
12–16 years 398 (57.8) 345 (53.4) ———— ——
Sex
Female 343 (49.8) 345 (53.4) 0.256 0.6
Male 346 (50.2) 301 (46.6) ———— ——
Distance from area of residence to Lake Victoria
≤5 km 330 (47.9) 300 (46.4) 0.037 0.8
>5 km 359 (52.1) 346 (53.6) ———— ——
aAdjusted for cluster design effectHowever, the occurrence of side-effects was unchanged in
the non-schools; 46.9 % (95 % CI 42.2–50.7 %) in 2013
and 53.2 % (95 % CI 48.5–57.9 %) (p = 0.443) in 2014. A
significant decrease in the proportion of children who re-
ported to have eaten something prior to mass treatment
was noted in both the snack and non-snack schools from
92.8 % (95 % CI 90.4–98.4) to 54.4 % (95 % CI 48.8–58.9 %)
(p < 0.001) in 2014 and from 49.8 % (95 % CI 45.5–54.1 %)
to 32.5 % (95 % CI 28.2–37.0 %) (p < 0.001) in 2013, re-
spectively. The frequency of side-effects in the snack and
non-snack schools in 2014 was comparable; 61.2 %
(95 % CI 56.2–66.1 %) and 53.2 % (95 % CI 48.5–57.9 %)
(p = 0.349), respectively. The proportion of children
who reported to have eaten something prior to mass
treatment in 2014 was 54.4 % (95 % CI 48.8–58.9 %) in
the snack schools compared to 32.5 % (95 % CI 28.2–
37.0 %) (p = 0.011) in the non-snack schools.
Prevalence and mean intensity of S. mansoni infection
Prevalence of S. mansoni infection in the snack schools
was unchanged;1.3 % (95 % CI 0.6–2.6 %) in 2013 and
7.5 % (95 % CI 5.3–10.1 %) (p = 0.051) in 2014. Similarly,
the prevalence of S. mansoni infection in the non-snack
schools was unchanged; 14.1 % (95 % CI 11.6–16.9 %) in
2013 and 22.0 % (95 % CI 18.8–25.4 %) (p = 0.141) in
2014. A statistically significant difference in the preva-
lence of S. mansoni infection was noted between the
snack and non-snack schools in 2014; 22.0 % (95 % CI
18.8–25.4 %) and 7.5 % (95 % CI 5.3–10.1 %) (p = 0.008),
respectively.
Although the mean intensity of S. mansoni infection
increased in both the snack and non-snack schools, the
differences did not reach statistical significance; 38.3
epg (95 % CI 21.8–67.2) in 2013 and 145.7 epg (95 %
CI 92.6–229.5) (p = 0.197) in 2014 and 78.4 epg (95 %
CI 60.6–101.5) in 2013 and 322.5 epg (95 % CI 258.1–
403.1) (p = 0.120) in 2014, respectively (Table 2).fter the 2013 and 2014 mass treatment
Snack schools
lue 2013 2014 χ2a p-Value
n = (595) (%) n = (496) (%)
38 310 (52.1) 241 (48.6) 0.190 0.663
—— 285 (47.9) 255 (51.4) ———— ————
13 296 (49.7) 270 (54.4) 0.349 0.555
—— 299 (50.3) 226 (45.6) ———— ————
47 284 (47.7) 243 (49.0) 0.021 0.885
—— 311 (52.3) 253 (51.0) ———— ————
Table 2 Characteristics of the snack and non-snack school after the 2013 and 2014 mass treatment
Characteristic Non-snack schools Snack schools
2013 2014 Test Statistica p-Value 2013 2014 Test Statistica p-Value
n = (689) (%) n = (646) (%) n = (595) (%) n = (496) (%)
Knowledge of schistosomiasis prevention (%)
Yes 595 (86.4) 362 (56.0) χ2 = 23.732 <0.001 500 (84.0) 308 (62.1) χ2 = 10.574 0.001
No 94 (13.6) 284 (44.0) ———— ———— 95 (16.0) 188 (37.9) ———— ————
Eaten food prior to mass treatment (%)
Yes 270 (49.8) 148 (32.5) χ2 = 4.708 0.030 519 (92.8) 211 (54.4) χ2 = 30.103 <0.001
No 272 (50.2) 307 (67.5) ———— ———— 40 (7.2) 177 (45.6) ———— ————
Self-reported uptake of praziquantel (%)
Yes 542 (78.7) 455 (70.4) χ2 = 1.829 0.176 559 (93.9) 387 (78.0) χ2 = 9.231 0.002
No 147 (21.3) 191 (29.6) ———— ———— 36 (6.1) 109 (22.0) ———— ————
Side-effects attributable to praziquantel (%)
Yes 254 (46.9) 242 (53.2) χ2 = 0.589 0.443 192 (34.3) 240 (61.2) χ2 = 10.486 0.001
No 288 (53.1) 213 (46.8) ———— ———— 367 (65.7) 152 (38.8) ———— ————
Reported side-effects attributable to praziquantel (%)
Abdominal pain 133 (52.4) 180 (74.4) χ2 = 6.195 0.013 109 (56.8) 157 (65.4) χ2 = 3.202 0.074
Dizziness 61 (24.0) 27 (11.2) ———— ———— 45 (23.4) 40 (16.7) ———— ————
Vomiting 19 (7.5) 11 (4.6) ———— ———— 7 (3.6) 25 (10.4) ———— ————
Diarrhoea 31 (12.2) 7 (2.9) ———— ———— 27 (14.1) 12 (5.0) ———— ————
Headache) 10 (3.9) 17 (7.0) ———— ———— 4 (2.1) 6 (2.5) ———— ————
S. mansoni infection status (%)
Positive 97 (14.1) 142 (22.0) χ2 = 2.165 0.141 8 (1.3) 37 (7.5) χ2 = 3.819 0.051
Negative 592 (85.9) 504 (78.0) ———— ———— 587 (98.7) 459 (92.5) ———— ————
Intensity of S. mansoni infection (epg)
GMI epg 78.4 322.5 t =2.412 0.120 38.3 145.7 t =1.662 0.197
aAdjusted for cluster design effect
Table 3 Estimated crude risk ratios (CRR) and adjusted risk
ratio (ARR) and their 95 % CI from the final logistic regression
mixed-effects model for treatment uptake
Variable CRR (95 % CI) p-Value ARR (95 % CI) p-Value
Distance from school to the lake
≤5 km 1.13 (1.03–1.24) 0.009 1.00 (0.99–1.00) 0.343
Sensitized about schistosomiasis prevention
Yes 1.38 (1.18–1.61) <0.001 1.01 (0.01–1.03) 0.247
Correct knowledge of schistosomiasis prevention
Yes 1.24 (1.13–1.36) <0.001 1.02 (0.99–1.04) 0.174
Eaten food prior to mass treatment
1.01 (1.00–1.02) 0.020 1.01 (1.00–1.02) 0.020
Adjusted for age and sex
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The proportion of children with correct knowledge of
schistosomiasis prevention in both the snack and non-
snack schools significantly reduced from 84.0 % (95 %
CI 80.5–87.1 %) in 2013 to 62.1 % (95 % CI 56.3–
67.5 %) (p < 0.001) in 2014 and from 86.4 % (95 % CI
83.4–89.0 %) in 2013 to 56.0 % (95 % CI 50.8–61.3 %)
(p < 0.001) in 2014, respectively. However, knowledge of
schistosomiasis prevention in the snack and non-snack
schools in 2014 was comparable; 62.1 % (95 % CI 57.7–
66.4 %) and 56.0 % (95 % CI 52.1–59.9 %) (p = 0.412),
respectively.
Predictors of uptake of praziquantel
Through a step wise backward elimination method, vari-
ables with p < 0.05 from the unadjusted model (distance
from school to the lake, sensitized about schistosomiasis,
knowledge of schistosomiaisis prevention and eaten food
prior to mass treatment) were considered for inclusion
into the multivariable adjusted model. The only variable
retained in the final model was eating food prior tomass treatment (adjusted risk ratio (ARR) 1.01, 95 % CI
1.01–1.02, p = 0.020) (Table 3).
Discussion
This study found that the 2014 uptake of praziquantel
was lower than the 2013 uptake although the prevalence
Muhumuza et al. BMC Infectious Diseases  (2015) 15:423 Page 6 of 8and intensity of S. mansoni infection was unchanged be-
tween the years. The reported frequency of side-effects
in 2014 was higher than that in 2013. Knowledge of
schistosomiasis prevention was lower in 2014 than in
2013.
The observed decrease in uptake of treatment in 2014
may be attributable to lack of food for mitigating the
side-effects of praziquantel. During the 2013 mass treat-
ment, food to alleviate the side-effects and motivate the
children to take treatment was provided to children with
high levels of success [27]. The fear of side-effects as a
major reason for non-uptake of praziquantel has been
previously reported [8, 11, 13]. Food high in carbohy-
drate content increases the absorption of praziquantel
form the gastro-intestinal tract, enhances its bioavailabil-
ity and lowers the odds of side-effects [14–16]. During
the 2014 mass treatment, only 54.4 % compared to
92.8 % of the children in the snack schools in 2013 re-
ported to have taken food prior to mass treatment, the
majority reporting maize porridge as the major type of
food taken. The other types of food reported included
pancakes, maize cobs and dry tea. This implies that a
large proportion of children in 2014 took treatment on
an empty stomach with the risk of widespread side-
effects. The drug distribution strategies in the non-snack
schools in 2013 and 2014 were similar, with no specific
measures to mitigate the side-effects and motivate chil-
dren to take treatment on both occasions. This probably
explains the unvarying uptake levels and occurrence of
side-effects among children in this group. These data
suggest that the reasons for the low uptake identified in
our previous studies [11, 13, 26] such as, inadequate in-
formation about schistosomiasis prevention, insufficient
preparation and facilitation of teachers to distribute
treatment and the fear of side-effects of praziquantel, es-
pecially when the drug is taken on an empty stomach
are probably accurate and the measures suggested, such
as provision of food in combination with education mes-
sages prior to treatment [27] are necessary to maintain
high treatment coverage. A detailed cost-effectiveness
analysis of provision of indigenous, locally available and
relatively low cost food, such as maize porridge, during
mass treatment should be undertaken and if found cost-
effective, provision of food should be integrated into
school-based mass treatment. A multi-pronged strategy
for provision of food by the national control program,
parents or the Government could be used.
The prevalence and intensity of S. mansoni infection
after mass treatment in 2013 and 2014 were unchanged
in both groups of schools. Although the realized uptake
in both the non-snack (70.4 %) and the snack schools
(78.0 %) during the 2014 mass treatment was lower
than the 2013 uptake (78.7 and 93.9 %), the 2014 up-
take was adequate to maintain the levels of infectionbut inadequate to significantly reduce the prevalence
rates and intensity of the infection. In high transmis-
sion areas, chemotherapy with praziquantel is effective
in reducing morbidity but the prevalence and intensity
of infection return to pre-treatment levels within a
short time if no other means of control are applied,
even when treatment coverage is high [33]. In the
study area, the majority of the children frequently visit
the lake to fetch water, bathe, wash, fish and to swim
[10, 11] and are thus at high risk of infection and re-
infection. Sustained drop in infection can be achieved
through a combination of interventions including pre-
ventive chemotherapy, health education, cessation of
poor human sanitation practices and improved access
to safe water [34, 35]. Each of these strategies is import-
ant but not sufficient when applied in isolation. Inad-
equate resources and capacity for such measures are
major obstacles to sustainable schistosomiasis control in
developing countries [36]. In the study area, school-based
mass treatment with praziquantel is the mainstay for
schistosomiasis control among school-age children. The
challenges associated with this strategy have been dis-
cussed elsewhere [6, 7, 37, 38].
Knowledge of schistosomiasis prevention in both
groups of schools in 2014 was considerably lower than
that in 2013, a manifestation of the insufficient health
education provided in 2014. Prior to the 2013 mass
treatment, education messages tailored to the knowledge
gap in schistosomiasis prevention were provided to all
children in both groups of schools with high levels of
knowledge registered in the schools. In 2014, less than a
half of the children in both the snack and non-snack
schools reported to have been sensitized about schisto-
somiasis prior to mass treatment. As such, a significant
reduction in the proportion of children with adequate
knowledge of schistosomiasis prevention was noted in
both groups of schools. Health education and other be-
havioural change interventions are effective strategies
for increasing compliance to treatment for schistosom-
iasis [39–41]. In the absence of these interventions,
there is a risk that the targeted populations may resist
treatment [9, 39].
Study limitations
Children who participated in both studies were selected
at random. It is possible that some of the children exam-
ined in 2013 could have been re-examined in 2014 and
provided similar responses on both occasions. However,
the correlation between self-reported uptake and S.
mansoni infection and intensity validated the self-
reported uptake as accurate. A negative linear relation-
ship between uptake of praziquantel and prevalence as
well as intensity of S. mansoni infection was observed:
In schools with high uptake, the prevalence and intensity
Muhumuza et al. BMC Infectious Diseases  (2015) 15:423 Page 7 of 8of S. mansoni infection was much lower than in schools
with low uptake. Secondly, the Kato-Katz technique
adopted for this study analyses a small amount of stool
(41.7 mg) and therefore has a relatively low capacity to
detect eggs from specimens of low intensity infections
[30, 42]. The sensitivity of the method was increased by
examining two stool samples from each child and pre-
paring two thick stool smears from each sample.
Conclusions
This study shows that in the absence of food to motivate
children to take treatment and to mitigate the side-effects
of praziquantel, uptake of praziquantel reduces and the
side-effects of the drug increase. Thus, strategies for main-
taining high treatment coverage are needed. Such strategies
should include continued sensitization and education of the
children and provision of food at school to mitigate the
side-effects attributable to praziquantel treatment and mo-
tivate children to take treatment.
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